Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Turkish Translation
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deleu, D.
Right arrow Articles by Colwell, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deleu, D.
Right arrow Articles by Colwell, A.
Related Collections
Right arrow Parkinson's disease/Parkinsonism
NEUROLOGY 2006;67:897-899
© 2006 American Academy of Neurology
Brief Communications

Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease

D. Deleu, MD, PhD, FAAN, FRCP, P. Jacob, MD, DM, P. Chand, DM, FAAN, FRCP, S. Sarre, PharmD, PhD and A. Colwell, PhD

From the Department of Neurology (Medicine) (D.D., P.J., P.C.) and Department of Biochemistry (A.C.), Sultan Qaboos University Hospital, Sultanate of Oman; and Department of Pharmaceutical Chemistry and Drug Analysis, School of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium (S.S.).

Address correspondence and reprint requests to Dr. Dirk Deleu, Department of Neurology (Medicine), P.O. Box 3050, Hamad Medical Corporation, Doha, State of Qatar; e-mail: doc_deleu{at}hotmail.com

The authors studied the acute effect of caffeine on the levodopa pharmacokinetics and pharmacodynamics in 12 patients with idiopathic Parkinson disease. This double-blind, randomized, crossover study revealed that caffeine shortened the maximal plasma concentration of levodopa, decreased the latency to levodopa walking and tapping motor response, and increased the magnitude of walking response. Caffeine administered before levodopa may improve its pharmacokinetics in some parkinsonian patients.

Disclosure: The authors report no conflicts of interest.

Received January 3, 2006. Accepted in final form May 8, 2006.




This article has been cited by other articles:


Home page
 NeurologyHome page
C. W. Olanow, M. B. Stern, and K. Sethi
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Neurology, May 26, 2009; 72(21_Supplement_4): S1 - S136.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
Minerva
BMJ, September 23, 2006; 333(7569): 662 - 662.
[Full Text] [PDF]